ArticleTranslational cancer research2026
KCNK9 could be a prognostic biomarker in uterine corpus endometrial carcinoma.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Uterine corpus endometrial carcinoma (UCEC) incidence is rising, necessitating novel prognostic biomarkers. Potassium two pore domain channel subfamily K member 9 (KCNK9) exhibits oncogenic functions in other cancers, but its prognostic and immunological roles in UCEC remain unclear. This study aimed to evaluate the prognostic significance of KCNK9 and its association with the tumor microenvironment (TME) in UCEC. Methods: We integrated multi-omics data from The Cancer Genome Atlas (TCGA) UCEC cohort (n=553 tumors, 35 normals). Differential expression, survival (Kaplan-Meier, Cox regression), and immune cell infiltration (CIBERSORT) analyses were performed. Findings were validated using an independent Gene Expression Omnibus (GEO) cohort (GSE17025, n=79 tumors, 12 normals) and immunohistochemistry (IHC) on patient-derived tissues. To explore potential causality and regulatory mechanisms, supplementary two-sample Mendelian randomization (MR), clustered regularly interspaced short palindromic repeats (CRISPR) dependency, and DNA methylation-expression correlation analyses were conducted. Results: KCNK9 was significantly overexpressed in UCEC at mRNA and protein levels (P<0.05). High KCNK9 expression correlated with advanced tumor grade and independently predicted reduced overall survival (OS) [adjusted hazard ratio (HR) =1.141, 95% confidence interval (CI): 1.063-1.223, P=0.0002] and progression-free survival (PFS) (adjusted HR =1.140, 95% CI: 1.064-1.222, P=0.0002). An immunosuppressive TME characterized by decreased cytotoxic T-cell infiltration was associated with high KCNK9. MR analysis suggested a potential causal link between genetically predicted KCNK9 expression and UCEC risk [inverse-variance weighted (IVW) odds ratio (OR) =1.0096, P=1.05×10 Conclusions: KCNK9 is a robust, independent prognostic biomarker linked to an immunosuppressive TME in UCEC. Supported by multi-omics and genetic evidence, KCNK9 is nominated as a high-priority candidate for future mechanistic and therapeutic exploration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.